Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: Fitzhughlaw who wrote (62994)	1/13/2025 7:48:18 PM
From: stockdoc77	10 Recommendations Recommended By Davidoff dorightbythem erickerickson erippetoe idahoranch1 and 5 more members Read Replies (1) \| Respond to of 63307

Don't know for sure but I think all the SAVA bulls have basically exited social media etc. What could they possibly say? The problem for them was not that they bet on the wrong horse (remember Emab or Vmab or the pancreatic CA radioactive Mab?), that is an inherent risk in biotech. Their real problem was how publicly bullish they were, how impervious they were to contrary evidence or concerning events, and how absolutely certain this drug would work for the biggest beast in medicine, Alzheimer's. It has been a graveyard of medical therapy, and even the Mabs that got approved don't actually do much. I don't see them being prescribed. Would be curious what kind of sales they are generating. To be successful in this space I think one must always be open to the null hypothesis, and that no matter how good P1 and P2 look, P3 is a roll of the dice and one should invest accordingly. We all made out like bandits on IMMU, but even though I closely followed IMMU-132 from when they reported the first mouse data, I was never absolutely certain we would have a positive P3. My game plan was for us to get AA and sell enough to never have to worry about money, and let the rest ride on the P3. In the end they bungled manufacturing, AA got delayed, and the P3 reported instead. I still shudder at the thought of the P3 being a failure. Right now my three biggest biotech investments have approved products and are ramping sales. I don't take big bets on P3 results. For me IMMU was just as much about getting lucky as being a smart investor.